Publikationen

• Ausgewählte Originalarbeiten
• Übersichtsarbeiten

2011

Krüger R, Sharma M, Riess O, Gasser T, van Broeckhoven C, Theuns J, Aasly JO, Annesi G, Bentivoglio AR, Brice A, Brighina L, Chartier-Harlin MC, Farrer M, Ferrarese C, Ferraris A, Hadjigeorgiou GM, Hattori N, Klein C, Lesage S, Lin JJ, Lynch T, Maraganore DM,  Mellick G, Nilsson C, Nuytemans K, Opala G, Prigione A, Quattrone A, Silburn PA, Tan EK, Toda T, Tomiyama H, Valente EM, Wirdefelt K, Wszolek ZK and Maraganore DM for the Genetic Epidemiology of Parkinson disease  consortium. (2011) A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson's disease. Neurobiol Aging 32: 548.e9–548.e18

Elbaz A, Ross O, Ioannidis JPA, Soto-Ortolaza AI, Moisan F, Aasly J, Annesi G, Bozi M, Brighina L, Chartier-Harlin MC, Destée A, Ferrarese C, Ferraris A, Gibson JM, Gispert S, Hadjigeorgiou GM, Jasinska-Myga B, Klein C, Krüger R, Lambert JC, Lohmann K, van de Loo S, Loriot MA, Lynch T, Mellick G, Mutez E, Nilsson C, Opala G, Puschmann A,  Quattrone A, Sharma M, Silburn PA, Stefanis L, Uitti RJ, Valente EM, Vilariño-Güell C, Wirdefeldt K, Wszolek ZK, Xiromerisiou G, Maraganore DM, Farrer MJ on behalf of the Genetic Epidemiology Of Parkinson’s Disease (GEO-PD) consortium. (2011) Independent and joint effects of the MAPT and SNCA genes in Parkinson’s disease. Ann Neurol 69:778-92.

Fitzgerald JC, Wu SH, Dunn L, Krüger R, Martins LM, Wood NW, Plun-Favreau H. (2011) Phosphorylation of HtrA2 by cyclin dependent kinase 5 modulates its neuroprotective function. Cell Death Differ (published online; doi: 10.1038/cdd.2011.90)

Nuber S, Petrasch-Parwez E, Arias-Carrion O, Hoeglinger G, Wurst C, Kohl Z, Schneider J, Calaminus C, Kahle PJ, Krüger R, Demietzel R, Samarina A, Fendt M, Nguyen H, von Hörsten S,  Teismann P, Velavan TP, Schmidt T, Winkler J, Riess O. (2011) Olfactorial Expression of Mutant A30P alpha-Synuclein in Conditional Mouse Brain: Implications for Early Stage of Parkinson’s Disease. Neurobiol disease; Neurobiol Dis 44:192-204

Sharma M, Gasser T, Maraganore DM, J Ioannidis, Riess O, van Broeckhoven C, Aasly J, Annesi G, Bentivoglio AR, Brice A, Brighina L, Djarmati A, Elbaz A, Farrer M, Ferrarese C, Gibson JM, Gispert S, Hattori N, Jasinska-Myga B, Klein C, Lesage S, Lynch T, , Mellick GD, Chartier-Harlin MC, de Nigris F, Opala G, Prigione A, Quattrone A, Roageva E, Ross O, Satake W, Silburn PA, Theuns J, Toda T, Tomiyama H, Wirdefeldt K, Wszolek Z and Krüger R on behalf of the Genetic Epidemiology of Parkinson disease  consortium. (2011) Role of sepiapterin reductase (SPR) gene at the PARK3 locus in Parkinson disease: A large multi-centre study. Neurobiol Aging 32: 2108.e1-5

Ross OA, Soto-Ortolaza AI, Aasly JO, Abahuni N, Annesi G, Bacon J, Bardien S, Bozi M, Brice A, Brighina L, van Broeckhoven C,Carr J, Chartier-Harlin MC, Dardiotis E, Diehl N, Ferrarese C, Ferraris A, Friske B, Gibson JM, Gibson R, Hadjigeorgiou GM, Hattori N, Heckman MG, Jasinska-Myga, B, Jeon BS, Kim YJ, Klein C, Krüger R, Kyratzi E, Lesage S, Lin CH, Lynch T, Maraganore DM,  Mellick G, Nilsson C, Nuytemans K, Opala G, Sup Park S, Pedersen NL, Puschmann A, Quattrone A, Sharma M, Silburn PA, Sohn YH, Stefanis L, Tadic V, Tomiyama H, Uitti R, Valente EM, van de Loo S, Vassilatis D, Vilariño-Güell C, White LR, Wirdefelt K, Wszolek ZK, Wu RM and Farrer MJ on behalf of the Genetic Epidemiology Of Parkinson’s Disease (GEOPD) consortium. (2011) LRRK2 exonic variants and susceptibility to Parkinson’s disease. Lancet Neurology 10: 898-908

Gispert S, Kurz A, Waibel S, Bauer P, Liepelt I, Geisen C, Gitler AD, Becker T, Weber M, Schulte C,  Berg D, Andersen PM, Krüger R, Riess O, Ludolph AC, Auburger G. (2011) The modulation of Amyotrophic Lateral Sclerosis risk by Ataxin-2 intermediate polyglutamine expansions is a specific effect. Neurobiol Dis 45: 356-61

Burbulla LF, Krüger R. (2011) Converging pathways of genes and environment in the pathogenesis of Parkinson’s disease. J Neurol Sci 306: 1-8

Sharma M, C, Aasly J, Annesi G, Bentivoglio AR, Brice A, Brighina L, Djarmati A, Elbaz A, Farrer M, Ferrarese C, Gibson JM, Gispert S, Hattori N, Jasinska-Myga B, Klein C, Lesage S, Lynch T, , Mellick GD, Chartier-Harlin MC, de Nigris F, Opala G, Prigione A, Quattrone A, Roageva E, Ross O, Satake W, Silburn PA, Theuns J, Toda T, Tomiyama H, Wirdefeldt K, Wszolek Z, Gasser T, Maraganore DM and Krüger R on behalf of the Genetic Epidemiology of Parkinson disease  consortium.  Large scale replication and heterogeneity in Parkinson’s disease genetic loci. Neurology (in press)

Sharma M,  Krüger R, Gasser T. LRRK2: Understanding the role of common and rare variants in Parkinson disease. Mov Disord (in press)

2010

Kieper N, Holmström K, Ciceri D, Fiesel F, Wolburg H, Ziviani E, Whitworth A, Martins LM, Kahle PJ, Krüger R. (2010) Modulation of mitochondrial function and morphology by interaction of Omi/HtrA2 with the mitochondrial fusion factor OPA1. Exp Cell Res 316: 1213-1224

Krebiehl G, Ruckerbauer S, Burbulla L, Kieper N, Maurer B, Waak J, Wolburg H, Gizatullina Z, Gellerich F, Woitalla D, Riess O, Kahle PJ, Proikas-Cezanne T, Krüger R. (2010) Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson’s disease-associated protein DJ-1. PLoS One 5: e9367

Seidel K, Schöls L, Nuber S, Petrasch-Parwez E, Gierga K, Wszolek Z, Dickson D, Gai WP, Bornemann A, Riess O, Rami A, den Dunnen WFA, Deller T, Rüb U, Krüger R. (2010) First appraisal of brain pathology owing to A30P mutant alpha-synuclein. Ann Neurol 67: 684-689

Burbulla LF, Schelling C, Kato H, Rapaport D, Woitalla D, Schiesling C, Schulte C, Sharma M, Bauer P, Jung S, Nordheim A, Schöls L, Riess O, Krüger R. (2010) Dissecting the Role of the Mitochondrial Chaperone Mortalin in Parkinson’s Disease – Functional Impact of Disease-Related Variants on Mitochondrial Homeostasis. Hum Mol Genet (published online 16.09.2010; doi:10.1093/hmg/ddq370)

2009

Sharma M, Lichtner P,  Krüger R, Berg D, Schulte C,  Illig T, Riess O, Gasser T. (2009) Further delineation of the association signal on chromosome 5 from the first whole genome association study in Parkinson's disease. Neurobiol Aging 30: 1706-9

Evangelou E , Maraganore DM, Annesi G, Brighina L, Brice A, Elbaz A, Ferrarese C, Hadjigeorgiou GM, Krüger R, Lambert JC, Lesage S, Markopoulou K, Mellick GD, Meeus B, Pedersen NL, Quatrone A, Sharma M, Silburn PA, Tan EK, Van Broeckhoven C, Wirdefeldt K, Ioannidis JPA, for the Genetic Epidemiology of Parkinson’s disease (GEOPD) consortium. (2009) Non-replication of association for 6 polymorphisms from meta-analysis of genome-wide association studies of Parkinson’s disease: large-scale collaborative study. Am J Med Genet B Neuropsychiatr Genet (published online May 27th)

Soehn AS, Franck T, Biskup S, Giaime E, Melle C, Rott R, Cebo D, Kalbacher H, Ott E, Pahnke J, Meitinger T, Krüger R, Gasser T, Berg D, von Eggeling F, Engelender S, Alves da Costa C, Riess O. (2009) Periphilin is a novel interactor of synphilin-1, a protein implicated in Parkinson's disease. Neurogenetics (published online September 3rd)

Nuber S, Franck T, Wolburg H, Schumann U, Chanarat S, Teismann P, Schulz JB, Luft AR, Tomiuk J, Wilbertz J, Bornemann A, Krüger R,  Riess O. (2009) Overexpression of the alpha-synuclein interacting protein Synphilin-1 leads to behavioural and neuropathological alterations in transgenic mice. Neurogenetics (in press)

Simon-Sanchez J, Schulte C, Bras CM, Sharma M, Gibbs R, Berg D, Paison-Ruiz C, Lichtner P, Scholz SW, Hernandez DG, Krüger R, Fedoroff M, Klein C, Goate A, Perlmutter J, Bonin M, Nalls MA, Illig T, Gieger C, Houlden H, Steffens M, Okun MS, Foote KD, Fernandez HH, Schreiber S, Arepalli S, Zonozi R, Gwinn K, Lopez G, Chanock SJ, Schatzkin A, Park Y, Hollenbeck A, Gao J, Huang X, Wood NW, Lorenz D, Deuschl G, Chen H, Riess O, Hardy JA, Singleton AB, Gasser T. (2009) Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat Genet (in press)

2008

Bonin M, Marx FP, Kautzmann S, Riess O, Krüger R. Microarray expression analysis reveals genetic pathways implicated in C621 Synphilin-1-mediated toxicity. J Neural Transm 2008;115:941-58

Radke S, Chander H, Schäfer P, Meiss G, Krüger R, Schulz JB, Germain D. Mitochondrial protein quality control by the proteasome involves ubiquitination and the protease Omi. J Biol Chem 2008;283:12681-12685

Wahl C, Kautzmann S, Strauss KM, Lang M, Schiessling C, Woitalla D, Müller T, Berger K, Niewar M, Bauer P, Riess O, Krüger R. A comprehensive genetic study of the proteasomal subunit S6 ATPase in German Parkinson’s disease patients. J Neural Transm 2008;115:1141-8

Kamm C, Fogel W, Wächter T, Schweitzer K, Berg D, Krüger R, Freudenstein D, Gasser T. Novel ATP1A3 mutation in a sporadic RDP patient with minimal benefit from deep brain stimulation. Neurology 2008;70:1501-1503

2007

Marx FP, Soehn AS, Berg D, Melle C, Schiesling C, Lang M, Kautzmann S, Strauss KM, Franck T, Engelender S, Pahnke J, Dawson S, von Eggeling F, Schulz JB, Riess O, Krüger R. The proteasomal subunit S6 ATPase is a novel synphilin-1 interacting protein – implications for Parkinson’s disease. FASEB J 2007;21:1759-1767  

Schweitzer KJ, Brüssel T, Leitner P, Krüger R, Bauer P, Gasser T, Berg D. Transcranial Ultrasound in different monogenetic subtypes of Parkinson’s Disease. J Neurol 2007;254:613-616

Abahuni N, Gispert S, Bauer P, Riess O, Krüger R, Becker T Auburger G. Mitochondrial translation initiation factor 3 gene polymorphism associated with Parkinson’s disease. Neurosci Lett 2007;414:126-129

Exner N, Treske B, Paquet D, Schiesling C, Holmström K, Gispert S, Carballo-Carbajal I, Berg D, Gasser T, Krüger R, Winklhofer KF, Vogel F, Reichert AS, Auburger G, Schmid B, Kahle PJ, Haass C. Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J Neurosci 2007;27:12413-12418.

2006

Maraganore DM, de Andrade M,  Elbaz A, Farrer MJ, Ioannidis JP, Krüger R, Rocca WA, Schneider NK, Lesnick TG, Lincoln SJ, Hulihan MM, Aasly JO, Ashizawa T, Chartier-Harlin MC, Checkoway H, Ferrarese C, Hadjigeorgiou G, Hattori N, Kawakami H, Lambert JC, Lynch T, Mellick GD, Papapetropoulos S, Parsian A, Quattrone A, Riess O, Tan EK, Van Broeckhoven C, on behalf of the Genetic Epidemiology of Parkinson’s Disease (GEO-PD) Consortium. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson’s disease. JAMA 2006;296:661-670

Elbaz A, Nelson LM, Payami H, Ioannidis JPA, Fiske BK, Annesi G, Carmine A, Factor SA, Ferrarese C, Hadjigeorgiou GM, Higgins D, Kawakami H, Krüger R, Marder K, Mayeux R, Mellick G, Nutt J, Ritz B, Samii A, Tanner CA, Van Broeckhoven C, Van Den Eeden SK, Wirdefeldt K, Zabetian C, Dehem M, Montimurro JM, Myers RM, Southwick A, Trikalinos TA. Whole-genome association and Parkinson’s disease: a large-scale international replication study. Lancet Neurology 2006;5:917-923

Franck T, Krüger R, Woitalla D, Müller T, Engelender S, Riess O. Mutation analysis of the seven in absentia homolog 1 (SIAH1) gene in Parkinson’s disease. J Neural Transm 2006;113:1903-1908

2005

Hofer A, Berg D, Asmus F, Niwar M, Ransmayr G, Riemenschneider M, Bonelli SP, Steffelbauer M, Ceballos-Baumann A, Häusermann P, Behnke S, Krüger R, Prestel J, Sharma M, Zimprich A, Riess O and Gasser T. The role of a-synuclein gene multiplications in early-onset Parkinson´s disease and dementia with Lewy bodies. J Neural Transm  2005;14:2099-2111

Berg D, Niwar N, Maass S, Zimprich A, Moeller C, Wuellner U, Klein C, Tan E, Schoels L, Marsh L, Dawson T, Janetzky B, Dufke A, Bauer P, Krüger R, Gasser T, Riess O. Mutations in the alpha-synuclein gene and Parkinson’s disease – implications from the screening of more than 1900 patients. Mov Disord 2005;20:1191-1194

Strauss KM, Martins LM,  Plun-Favreau H, Marx FP, Kautzmann S, Berg D, Gasser T, Wszolek Z, Müller T, Bornemann A, Wolburg H, Downward J, Riess O, Schulz JB, Krüger R. Loss of function mutation in the gene encoding Omi/HtrA2 in Parkinson’s disease. Hum Mol Genet 2005;14:2099-2111

Hochstrasser H, Tomiuk J, Walter U, Behnke S, Spiegel J, Krüger R, Becker G, Riess O, Berg D.  Functional relevance of ceruloplasmin mutations in Parkinson´s disease. FASEB J 2005;19:1851-1853

2004

Maraganore DM, Lesnick TG, Elbaz A, Chartier-Harlin MC, Gasser T, Krüger R, Hattori N, Mellick GD, Quattrone A, Satoh JI, Toda T, Wang J, Ioannidis JPA, de Andrade M, Rocca WA, the UCHL1 Global Genetics Consortium. UCHL1 is a Parkinson’s disease susceptibility gene. Ann Neurol 2004;55: 512-521

Hering R, Petrovic S, Mietz EM, Holzmann C, Berg D, Bauer P, Woitalla D, Müller T, Berger K, Krüger R, Riess O. Extended mutation analysis and association studies of Nurr1 (NR4A2) in Parkinson’s Disease. Neurology 2004;62:1231-1232

Glass A, Huynh DP, Franck T, Woitalla D, Müller T, Pulst SM, Berg D, Krüger R, Riess O. Screening for mutations in Synaptotagmin XI in Parkinson’s disease. J Neural Transm 2004;68:21-28

Müller T, Przuntek H, Krüger R, Mackowiak A. Antiapoptotic effects of budipine. J Neural Transm 2004;111:1365-1373

Hering R, Strauss K, Tao X, Bauer A, Mietz EM, Petrovic S, Bauer P, Schaible W, Woitalla D, Müller T, Schöls L, Klein C, Berg D, Meyer PT, Schulz JB, Wollnik B, Tong L, Krüger R, Riess O. Novel E64D mutation in DJ-1 gene is causative of early onset Parkinson’s Disease. Hum Mutat 2004;24:321-329

2003

Marx FP, Holzmann C, Strauss KM, Li L, Eberhardt O, Gerhardt E, Cookson MR, Hernandez D, Farrer MJ, Kachergus J, Engelender S, Ross CA, Berger K, Schöls L, Schulz JB, Riess O, Krüger R. Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson’s disease. Hum Mol Gen 2003;12:1223-1231

Holzmann C, Krüger R, Saecker AM, Schmitt I, Schöls L, Berger K, Riess O. Polymorphisms of the alpha-synuclein promoter: expression analyses and association studies in Parkinson’s disease. J Neural Transm 2003;110:67-76

Kobayashi H, Krüger R, Markopoulou K, Wszolek Z, Chase B, Taka H, Mineki R, Murayama K, Riess O, Mizuno Y, Hattori N. Haploinsufficiency at the alpha-synuclein gene underlies phenotypic severity in familial Parkinson’s disease. Brain 2003;126:32-42

Schulte T, Böhringer S, Schöls L, Müller T, Fischer C, Riess O, Przuntek H, Berger K, Epplen JT, Krüger R. Modulation of disease risk according to a cathepsin D / apolipoprotein E genotype in Parkinson’s disease. J Neural Transm 2003;110:749-755

Krüger R, Fischer C, Schulte T, Strauss K, Müller T, Woitalla D, Berg D, Hungs M, Gobbele R, Berger K, Epplen JT, Riess O, Schöls L. Mutations in the neurofilament M gene in Parkinson’s disease. Neurosci Lett 2003;351:125-129

2002

Schulte T, Schöls L, Müller T, Woitalla D, Berger K, Krüger R. Polymorphisms in the interleukin-1 alpha and beta genes and the risk for Parkinson’s disease. Neurosci Lett  2002;236:70-72

Rahner N, Holzmann C, Krüger R, Schöls L, Berger K, Riess O. Mutation analysis and association studies of neurofilament L in Parkinson’s disease. Brain Res 2002;951:82-87

Wintermeyer P, Riess O, Schöls L, Przuntek H, Miterski B, Epplen JT, Krüger R. Mutation analysis and association studies of nuclear factor-kappaB1 in German Parkinson‘s disease patients. J Neural Transm 2002;109:1181-1188

Ubl A, Berg D, Holzmann C, Krüger R, Berger K, Arzberger T, Bornemann A, Riess O. 14-3-3 is a component of Lewy bodies in Parkinson’s disease - mutation analysis and association studies of 14-3-3 eta. Brain Res Mol Brain Res 2002;108:33-39

2001

Krüger R, Kuhn W, Leenders KL, Sprengelmeyer R, Müller T, Woitalla D, Portman AT, Maguire RP, Veenma L, Schröder U, Schöls L, Epplen JT, Riess O, Przuntek H. Familial parkinsonism with synuclein pathology – clinical and PET studies of Ala30Pro mutation carriers. Neurology 2001;56:1355-1362

Krüger R, Schöls L, Müller T, Kuhn W, Woitalla D, Przuntek H, Epplen JT, Riess O. Evaluation of the alpha-synuclein gene in German Parkinson’s disease patients. Neurosci Lett 2001;310:191-193

2000

Krüger R, Menezes-Saecker AM, Schöls L, Kuhn W, Müller T, Woitalla D, Berg D, Berger K, Przuntek H, Epplen JT, Riess O. Genetic analysis of the alpha2-macroglobulin gene in early- and late-onset Parkinson’s disease. NeuroReport 2000;11:2439-2442

Krüger R, Hardt C, Tschentscher F, Jäckel S, Kuhn W, Müller T, Werner J, Woitalla D, Berg D, Kühnl N, Fuchs GA, Santos EJ, Przuntek H, Epplen JT, Schöls L, Riess O. Genetic analysis of immunomodulating factors in sporadic Parkinson’s disease. J Neural Transm 2000;107:553-562

Miterski B, Krüger R, Wintermeyer P, Epplen JT. PCR/SSCP detects reliably and efficiently DNA sequence variations in large scale screening projects. Comb Chem High Throughput Screening 2000;3:211-218

Wintermeyer P, Krüger R, Kuhn W, Müller T, Woitalla D, Berg D, Becker G, Leroy E, Polymeropoulos M, Berger K, Przuntek H, Schöls L, Epplen JT, Riess O. Mutation analysis and association studies of the UCHL1 gene in German Parkinson’s disease patients. NeuroReport 2000;11:2079-2082

Schöls L, Peters S, Szymanski S, Krüger R, Lange S, Hardt C, Riess O, Przuntek H. Extrapyramidal motor signs in degenerative ataxias. Arch Neurol 2000;57:1495-1500

1999

Krüger R, Vieira-Saecker AMM, Kuhn W, Berg D, Müller T, Kühnl N, Fuchs GA, Storch A, Hungs M, Woitalla D, Przuntek H, Epplen JT, Schöls L, Riess O. Increased susceptibility to sporadic Parkinson’s disease by a certain combined alpha-synuclein/apolipoprotein E genotype. Ann Neurol 1999;45:611-617

Krüger R, Vieira-Säcker AMM, Kuhn W, Müller T, Woitalla D, Schöls L, Przuntek H, Epplen JT, Riess O. Analysis of the parkin deletion in sporadic and familial Parkinson’s disease. J Neural Transm 1999;106:159-163

Grasbon-Frodl EM, Egensperger R, Kösel S, Krüger R, Riess O, Mehrain P, Graeber MB. The alpha-antichymotrypsin A-allele in German Parkinson disease patients. J Neural Transm 1999;106:729-736

1998

Krüger R, Kuhn W, Müller T, Woitalla D, Graeber M, Kösel S, Przuntek H, Epplen JT, Schöls L, Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat Genet 1998;18:106-108

Schöls L, Krüger R, Amoiridis G, Przuntek H, Epplen JT, Riess O. Spinocerebellar ataxia type 6: genotype and phenotype in German kindreds. J Neurol Neurosurg Psychiatry 1998;64:67-73

Burbulla LF, Krebiehl G, Krüger R. Balance is the challegenge – the impact of mitochondrial dynamics in Parkinson’s disease. Eur J Clin Invest (published online 03.08.2010)

Krüger R. LRRK2 in Parkinson’s disease – drawing the curtain of penetrance. BMC Medicine 2008;6:30

Schiesling C, Kieper N, Seidel K, Krüger R. Familial PD - genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease. Neuropathol and Appl Neurobiol 2008;34:255-271

Krüger R, Berg D, Riess O, Riederer P. (2007) Update on Parkinson’s disease genetics. Handbook of Neurochemistry and Molecular Neurobiology, 3rd edition, Lajtha ed, Springer Verlag, New York (in press)

Riess O, Krüger R, Hochstrasser H, Soehn AS, Nuber S, Franck T, Berg D. Genetic causes of Parkinson’s disease: extending the pathway. J Neural Transm 2006;70:181-189

Krüger R. Genetics of Parkinson’s disease. Molecular Bases of Neuro-degeneration, Savetteri G and Di Liegro I eds, Research Signpost, Kerala, 2005 pp 1-19

Storch A, Hofer A, Krüger R, Schulz JB, Winkler J, Gerlach M. New developments in diagnosis and treatment of Parkinson's disease - from basic science to clinical applications. J Neurol. 2004;251 (Suppl 6):VI/33-8

Krüger R. Genes in familial parkinsonism and their role in sporadic Parkinson’s disease. J Neurol 2004;251(Suppl 6):VI/2-VI/6

Krüger R. Causes of Parkinson’s disease: The role of synphilin-1 in synaptic function and protein degradation. Cell Tiss Res 2004;318:195-199

Krüger R. Parkinson disease, genetic types. Orphanet Encyclopedia, 2003; www.orpha.net/data/patho/GB/uk-Parkinson.pdf

Riess O, Berg D, Krüger R, Schulz JB. Therapeutic strategies for Parkinson’s disease based on data derived from genetic research. J Neurol 2003;250(Suppl 1):I3-I10

Riess O, Krüger R, Schulz JB. Spectrum of phenotypes and genotypes in Parkinson’s disease. J Neurol 2002;249(Suppl 3):III/15-III/20

Krüger R, Riess O. PARK3, Ubiquitin hydrolase L1 mutations and other PD loci. In: Pulst S (ed) Genetics of Movement Disorders. Elsevier Science/Academic Press, London, 2002;315-323

Krüger R. Progressive supranukleäre Blickparese. In: Schöls L, Riess O (eds) Neurogenetik. Kohlhammer Verlag, Stuttgart, 2002;334

Krüger R. Frontotemporale Demenz und Parkinsonismus. In: Schöls L, Riess O (eds) Neurogenetik. Kohlhammer Verlag, Stuttgart, 2002;141-144

Krüger R, Schöls L, Riess O. Idiopathisches Parkinson-Syndrom. In: Schöls L, Riess O (eds) Neurogenetik. Kohlhammer Verlag, Stuttgart, 2002;326-333

Krüger R, Schulz JB. The alpha-synuclein pathway to neurodegeneration. In: Tolosa E, Schulz JB, McKeith IG, Ferrer I (eds) Neurodegenerative disorders associated to alpha-synuclein pathology. Medicina stm Editores, Barcelona, 2002;1-21

Krüger R, Eberhardt O, Riess O, Schulz JB. Parkinson’s disease: one biochemical pathway to fit all genes? Trends Mol Med 2002;8:236-240

Riess O, Krüger R, Schöls L, Kösel S, Graeber M. Zur Genetik und Pathogenese des Morbus Parkinson. Dt Ärzteblatt 2000;3:A2739-2748

Riess O, Kuhn W, Krüger R. Genetic influence on the development of Parkinson’s disease. J Neurol 2000;247(Suppl 2):II69-II74

Krüger R, Müller T, Riess O. Involvement of a-synuclein in Parkinson’s disease and other neurodegenerative disorders. J Neural Transm 2000;107(Suppl):31-40

Riess O, Krüger R. Parkinson’s disease - a multifactorial neurodegenerative disorder. In: H. Przuntek, T Müller (eds) Diagnosis and treatment of Parkinson’s disease – state of the art. Springer, Wien New York, 1999;113-126

Krüger, R. Alpha-Synucléine et connexion génétique entre les maladies de Parkinson et d’Alzheimer. Fondation Ipsen – Alzheimer Actualités 1999;142: 6-12

Riess O, Jakes R, Krüger R. Genetic dissection of familial Parkinson’s disease. Mol Med Tod 1998;4:438-444

Müller T, Krüger R, Przuntek H, Kuhn W. Inhibition of tumor necrosis factor-a and interleukin-6 synthesis by Budipine. In: Korczyn AD (ed) Fourth Congress of the European Society for Clinical Neuropharmacology. Monduzzi Editore, Bologna, 1997;103-106